- Email: [email protected]
Novozymes results forecast for 1H 2007 and 2Q 2007
FOCUS Catalin funded by private venture capital and Iowa State Ames, IA, US-based Catilin has received $3 M in Series A funding from lead investor Mohr Davidow Ventures as well as from the Iowa State University. The company is using nanomaterial catalysts to make biodiesel production cheaper and hasten the process. The technology minimizes the number of synthesis steps and the use of raw material. Nanotech Report (Forbes/Wolfe), Jul 2007, 6 (7), 7
Degussa names new boss of exclusive synthesis Degussa generated sales of around €520 M ($716 M) from its exclusive synthesis and catalysts operations in 2006. The business concentrates on customer-specific production of chemical catalysts and pharma active ingredients and intermediates. The company has also appointed a new head for its synthesis business line on 1 Jul 2007. Chemical Week, 25 Jul 2007 (Website: http://www.chemweek.com)
Jacobs receives two sulfur recovery project contracts in China Jacobs Engineering Group Inc (Jacobs) announced that it received two contracts from Hofung Technology to provide Jacobs’ patented sulfur recovery technologies, Euroclaus and Superclaus, for two separate projects in China. Hofung Technology is a Dutch company specializing in marketing and sales of technology and equipment for the chemical, petrochemical, power, and energy industries, with operations in China. They are a sub-licensor of Jacobs’ technologies through Comprimo Sulfur Solutions Group. The two firms have partnered since 1992 to provide these two technologies to clients in China. Press release from: Jacobs Engineering Group Inc, 1111, South Arroyo Parkway, PO Box 7084, Pasadena, CA 91109 7084, USA. Tel: +1 626 578 3500. Fax: +1 626 578 6916. E-mail: [email protected]. Website: http://www.jacobs.com (7 Aug 2007)
Johnson Matthey interim management statement Apr-Jun 2007 Commenting on current trading at the Annual General Meeting held at 12.00
OCTOBER 2007
ON
C ATA LY S T S
noon on 24 Jul 2007, Sir John Banham, Chairman of Johnson Matthey, will provide the following statement: “Johnson Matthey has made a good start to the new financial year. In 1Q 2007 (period ends 30 Jun 2007) sales for the continuing businesses grew by 9%. Sales excluding the value of precious metals increased by 28%, with most of the growth in Environmental Technologies Division. Profit before tax for the continuing businesses was up 12% compared with 1Q 2006. The new Environmental Technologies Division achieved strong sales growth in the quarter. Emission Control Technologies (ECT) was well ahead, with good demand for heavy duty diesel catalysts for new vehicles in both Europe and North America following the introduction of new emission standards last year. Sales of catalysed soot filters for light duty diesel vehicles were also well up. Process Technologies’ sales were ahead of expectations but slightly down on the very strong 1Q 2006. Orders for 2Q 2007 are encouraging and the business should achieve good growth for 1H 2007. On 4 May 2007 the company sold its Hong Kong gold refinery which reduced sales growth in Precious Metal Products Division but operating profit for the division for 1Q 2007 was well ahead of 1Q 2006. Platinum group metal prices were stronger than in the same period last year but were less volatile. The division’s manufacturing businesses continued to perform very well. Fine Chemicals & Catalysts Division made an encouraging start to the year with good sales of catalysts and continued recovery in the US Pharmaceutical Materials business”. Johnson Matthey Interim Management Statement AprJun 2007, 24 Jul 2007 (Johnson Matthey Plc, 2-4 Cockspur Street, Trafalgar Square, London, SW1Y 5BQ. UK. Tel: +44 20 7269 8400. Fax: +44 20 7269 8433. Website: http://www.matthey.com)
New line of user-friendly metathesis catalysts Johnson Matthey Catalysts has licensed JM RCM 900, a new line of easy-to-use catalysts for ring closing and cross metathesis in pharmaceuticals. The new class of catalysts bearing bidentate pyridinealkoxide ligands has been developed by Ciba Specialty Chemicals. Manufacturing Chemist, Jul/Aug 2007, 79 (7), 10
Marathon chooses contractors Shell Global Solutions (US) Inc and Criterion Catalysts & Technologies have forged a deal to license technology and supply catalysts, reactor internals, a process design package, and technical services to Marathon Oil Corp’s new hydrocracker. The unit was built at Marathon’s 245,000 bbl/day refinery in Garyville, LA, USA. The expansion is expected to raise the site’s crude throughput by 180,000 bbl/day, boosting fuel output by 7.5 M gallon/day. Hydrocarbon Processing, Jul 2007, 86 (7), 33
Novozymes results forecast for 1H 2007 and 2Q 2007 Analysts are forecasting sales of DKR 3749 M for Novozymes in 1H 2007, compared with DKR 3282 M in 1H 2006. Operating results were up from DKR 657 M to DKR 783 M. The company is predicting a turnover growth of 11-13% in local currencies for the whole of 2007 and a growth of 8-10% in Danish currency, equivalent to DKR 7346-7482 M; analysts are expecting DKR 7506 M. Novozymes is forecasting an 11-13% increase in operating result to DKR 1487-1514 M in 2007, while analysts are expecting DKR 1512 M. Sales of technical enzymes totalling DKR 1095 M are predicted by analysts for 1H 2007, compared with DKR 922 M in 1H 2006, with an increase from DKR 469 M in 2Q 2006 to DKR 553 M in 2Q 2007 also forecast. Dagbladet Borsen, 6 Aug 2007 (Website: http://www.borsen.dk) (in Danish)
Novozymes forecasts growth in enzymes for ethanol production Novozymes is predicting a 40% growth in sales of enzymes for the production of fuel from grain products in 2007, followed by a 20-25%/y increase subsequent years. Sales of enzymes for washing products are also expected to grow whereas a fall is expected in sales of microorganisms and technical enzymes, excluding enzymes for fuel production. Dagbladet Borsen, 8 Aug 2007 (Website: http://www.borsen.dk) (in Danish)
3
Degussa names new boss of exclusive synthesis Degussa generated sales of around €520 M ($716 M) from its exclusive synthesis and catalysts operations in 2006. The business concentrates on customer-specific production of chemical catalysts and pharma active ingredients and intermediates. The company has also appointed a new head for its synthesis business line on 1 Jul 2007. Chemical Week, 25 Jul 2007 (Website: http://www.chemweek.com)
Jacobs receives two sulfur recovery project contracts in China Jacobs Engineering Group Inc (Jacobs) announced that it received two contracts from Hofung Technology to provide Jacobs’ patented sulfur recovery technologies, Euroclaus and Superclaus, for two separate projects in China. Hofung Technology is a Dutch company specializing in marketing and sales of technology and equipment for the chemical, petrochemical, power, and energy industries, with operations in China. They are a sub-licensor of Jacobs’ technologies through Comprimo Sulfur Solutions Group. The two firms have partnered since 1992 to provide these two technologies to clients in China. Press release from: Jacobs Engineering Group Inc, 1111, South Arroyo Parkway, PO Box 7084, Pasadena, CA 91109 7084, USA. Tel: +1 626 578 3500. Fax: +1 626 578 6916. E-mail: [email protected]. Website: http://www.jacobs.com (7 Aug 2007)
Johnson Matthey interim management statement Apr-Jun 2007 Commenting on current trading at the Annual General Meeting held at 12.00
OCTOBER 2007
ON
C ATA LY S T S
noon on 24 Jul 2007, Sir John Banham, Chairman of Johnson Matthey, will provide the following statement: “Johnson Matthey has made a good start to the new financial year. In 1Q 2007 (period ends 30 Jun 2007) sales for the continuing businesses grew by 9%. Sales excluding the value of precious metals increased by 28%, with most of the growth in Environmental Technologies Division. Profit before tax for the continuing businesses was up 12% compared with 1Q 2006. The new Environmental Technologies Division achieved strong sales growth in the quarter. Emission Control Technologies (ECT) was well ahead, with good demand for heavy duty diesel catalysts for new vehicles in both Europe and North America following the introduction of new emission standards last year. Sales of catalysed soot filters for light duty diesel vehicles were also well up. Process Technologies’ sales were ahead of expectations but slightly down on the very strong 1Q 2006. Orders for 2Q 2007 are encouraging and the business should achieve good growth for 1H 2007. On 4 May 2007 the company sold its Hong Kong gold refinery which reduced sales growth in Precious Metal Products Division but operating profit for the division for 1Q 2007 was well ahead of 1Q 2006. Platinum group metal prices were stronger than in the same period last year but were less volatile. The division’s manufacturing businesses continued to perform very well. Fine Chemicals & Catalysts Division made an encouraging start to the year with good sales of catalysts and continued recovery in the US Pharmaceutical Materials business”. Johnson Matthey Interim Management Statement AprJun 2007, 24 Jul 2007 (Johnson Matthey Plc, 2-4 Cockspur Street, Trafalgar Square, London, SW1Y 5BQ. UK. Tel: +44 20 7269 8400. Fax: +44 20 7269 8433. Website: http://www.matthey.com)
New line of user-friendly metathesis catalysts Johnson Matthey Catalysts has licensed JM RCM 900, a new line of easy-to-use catalysts for ring closing and cross metathesis in pharmaceuticals. The new class of catalysts bearing bidentate pyridinealkoxide ligands has been developed by Ciba Specialty Chemicals. Manufacturing Chemist, Jul/Aug 2007, 79 (7), 10
Marathon chooses contractors Shell Global Solutions (US) Inc and Criterion Catalysts & Technologies have forged a deal to license technology and supply catalysts, reactor internals, a process design package, and technical services to Marathon Oil Corp’s new hydrocracker. The unit was built at Marathon’s 245,000 bbl/day refinery in Garyville, LA, USA. The expansion is expected to raise the site’s crude throughput by 180,000 bbl/day, boosting fuel output by 7.5 M gallon/day. Hydrocarbon Processing, Jul 2007, 86 (7), 33
Novozymes results forecast for 1H 2007 and 2Q 2007 Analysts are forecasting sales of DKR 3749 M for Novozymes in 1H 2007, compared with DKR 3282 M in 1H 2006. Operating results were up from DKR 657 M to DKR 783 M. The company is predicting a turnover growth of 11-13% in local currencies for the whole of 2007 and a growth of 8-10% in Danish currency, equivalent to DKR 7346-7482 M; analysts are expecting DKR 7506 M. Novozymes is forecasting an 11-13% increase in operating result to DKR 1487-1514 M in 2007, while analysts are expecting DKR 1512 M. Sales of technical enzymes totalling DKR 1095 M are predicted by analysts for 1H 2007, compared with DKR 922 M in 1H 2006, with an increase from DKR 469 M in 2Q 2006 to DKR 553 M in 2Q 2007 also forecast. Dagbladet Borsen, 6 Aug 2007 (Website: http://www.borsen.dk) (in Danish)
Novozymes forecasts growth in enzymes for ethanol production Novozymes is predicting a 40% growth in sales of enzymes for the production of fuel from grain products in 2007, followed by a 20-25%/y increase subsequent years. Sales of enzymes for washing products are also expected to grow whereas a fall is expected in sales of microorganisms and technical enzymes, excluding enzymes for fuel production. Dagbladet Borsen, 8 Aug 2007 (Website: http://www.borsen.dk) (in Danish)
3